The global precision oncology market size is expected to reach USD 202.0 billion and expand at a CAGR of 9.7% from 2023 to 2030, based on a new report by Grand View Research, Inc. Precision oncology is a growing field where the market products emphasize on molecular profiling of tumors to identify alterations in the gene. Currently, the industry has witnessed major success with a 95% response rate being observed in patients along with extended quality-adjusted life. The market products offer the potential for improved patient care and a better-informed decision-making experience in hospitals and clinics. Alternatively, the increasing prevalence of cancer across the globe, the rising number of clinical trial studies, and the rapid adoption of technology in precision oncology diagnostic is anticipated to boost the market demand.
Due to the COVID-19 pandemic, the precision oncology market had a huge impact as the pandemic exaggerated healthcare across the globe for people living with cancer, possessing a unique set of challenges. Besides, delayed diagnosis and therapeutics using precision oncology have affected cancer patient diagnosis and treatment to a major extent. However, post-COVID-19 pandemic, the market has gained rapid demand as precision oncology offers better therapeutic outcomes and improves the quality of patient life for cancer patients.
In January 2022, OncXerna Therapeutics, Inc. and Exact Sciences Corp. mentioned the agreement to introduce OncXerna’s TME Panel lab services for patients in the U.S. It is an innovative gene expression score, which helps identify patients to respond to immunotherapies and anti-angiogenic. Further, the company added that it believes to provide clinician access to the Xerna TME Panel through biopharma partners as a companion diagnostic and existing precision oncology team.
Request a free sample copy or view report summary: Precision Oncology Market Report
Based on product type, the therapeutics segment held the majority of the market share of around 71.7% in 2022 attributed to its rising number of approvals of therapies has benefited the market demand
Based on cancer type, the breast cancer segment dominated the market in terms of revenue share in 2022 owing to the rising incidence of breast cancer, expanding research activities, evolved diagnostics, and overall patient prognosis is likely to drive the market
Based on end-use, the hospitals & clinics segment accounted for the largest market share of around 46.8% in 2022 owing to the growing focus on components such as precision planning, precise diagnosis and monitoring, precise treatment
In 2022, North America dominated the market in terms of revenue with a share of around 42.5% due to trending factors such as rising healthcare expenditure, and evolving healthcare landscape, changing competitive landscape of the precision oncology market in U.S. and Canada
Grand View Research has segmented the global precision oncology market based on product type, cancer type, end-use, and region:
Precision Oncology Product Type Outlook (USD Million, 2017 - 2030)
Diagnostics
Therapeutics
Precision Oncology Cancer Type Outlook (Revenue, USD Million, 2017 - 2030)
Breast Cancer
Colorectal Cancer
Cervical Cancer
Prostate Cancer
Lung Cancer
Others
Precision Oncology End-use Outlook (Revenue, USD Million, 2017 - 2030)
Hospitals & Diagnostic Laboratories
Pharmaceutical & Biotechnology Companies
Healthcare Data Companies
Precision Oncology Regional Outlook (Revenue, USD Million, 2017 - 2030)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
Thailand
South Korea
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players of Precision Oncology Market
Thermo Fisher Scientific Inc.
Invitae Corporation
Qiagen N.V.
Illumina, Inc.
Laboratory Corporation Of America Holding
Exact Sciences Corporation
Rain Oncology Inc.
Strata Oncology, Inc.
Xilis, Inc.
Variantyx, Inc.
Bioserve
Relay Therapeutics
Acrivon Therapeutics
"The quality of research they have done for us has been excellent..."